[
  {
    "ts": null,
    "headline": "What RFK Jr.’s Dislike for Drug TV Commercials Could Mean for the Ad Industry",
    "summary": "Robert F. Kennedy Jr.’s stated desire to ban drug commercials from TV seems unlikely to become reality, according to advertising experts, but even pressure from Washington that falls short of an outright ban could lead to changes in the multibillion-dollar advertising sector.",
    "url": "https://finnhub.io/api/news?id=ca1e066b2216fd29007046fea6502325983d0b7d812c1be3e10f5b2fd672ce86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735845000,
      "headline": "What RFK Jr.’s Dislike for Drug TV Commercials Could Mean for the Ad Industry",
      "id": 132243650,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Robert F. Kennedy Jr.’s stated desire to ban drug commercials from TV seems unlikely to become reality, according to advertising experts, but even pressure from Washington that falls short of an outright ban could lead to changes in the multibillion-dollar advertising sector.",
      "url": "https://finnhub.io/api/news?id=ca1e066b2216fd29007046fea6502325983d0b7d812c1be3e10f5b2fd672ce86"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c42e6267c903eb24a3ae2e42d6b50daddc5d0f45827ec6d69ad42c9d72a75829",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735835700,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 132322052,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c42e6267c903eb24a3ae2e42d6b50daddc5d0f45827ec6d69ad42c9d72a75829"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
    "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
    "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735825260,
      "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
      "id": 132242207,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a"
    }
  }
]